Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 08 2020 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, ocular surface diseases and
retinal diseases, today announced that the Company will participate
in the following virtual investor conferences in September.
- Citi 15th Annual BioPharma Conference
- Date: Thursday, September 10, 2020
- Time: 9:50 a.m. Eastern Time
- Panel Discussion: Ophthalmology – Seeing 20/20 in 2020
- Panelist: Vicente Anido, Jr., Ph.D., Chairman and Chief
Executive Officer
- H.C. Wainwright 22nd Annual Global Investment Conference
- Date: Tuesday, September 15, 2020
- Time: 1:30 p.m. Eastern Time
- Presenter: Richard J. Rubino, Chief Financial Officer
- Presentation Type: Fireside
- Cantor Global Healthcare Conference
- Date: Wednesday, September 16, 2020
- Time: 10:40 a.m. Eastern Time
- Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief
Executive Officer
- Presentation Type: Fireside
The panel and fireside discussions will be webcast live and may
be accessed by visiting Aerie’s website at
http://investors.aeriepharma.com. A replay of the webcast will be
available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
ocular surface diseases and retinal diseases. Aerie’s first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United
States in April 2018. In clinical trials of Rhopressa®,
the most common adverse reactions were conjunctival hyperemia,
corneal verticillata, instillation site pain, and conjunctival
hemorrhage. More information about Rhopressa®, including the
product label, is available at www.rhopressa.com. Aerie’s
second product for the reduction of elevated IOP in patients with
open-angle glaucoma or ocular hypertension,
Rocklatan® (netarsudil and latanoprost ophthalmic solution)
0.02%/0.005%, the first and only fixed-dose combination of
Rhopressa® and the widely-prescribed PGA (prostaglandin
analog) latanoprost, was launched in the United
States in May 2019. In clinical trials of Rocklatan®, the
most common adverse reactions were conjunctival hyperemia, corneal
verticillata, instillation site pain, and conjunctival hemorrhage.
More information about Rocklatan®, including the product label, is
available at www.rocklatan.com. Aerie continues to focus on
global expansion and the development of additional product
candidates and technologies in ophthalmology, including for wet
age-related macular degeneration and diabetic macular edema. More
information is available at www.aeriepharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005025/en/
Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949;
abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024